The best model included the following variables: initial serum CA-125 levels (≥700 vs. <700 IU/mL), germline BRCA1/2 mutational status (mutation vs. wild-type), residual tumor after surgery (gross vs. no gross), FIGO stage (III–IV vs. I–II), and expression levels (high or low) of the six protein biomarkers on IHC staining of ovarian cancer tissue. The gene discussed is BRCA1; the disease is ovarian carcinoma.